AMLX
Amylyx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$33.81
+0.06 (+0.18%)
Current Price
| Previous Close | $33.75 |
| Open | $33.49 |
| Day High | $34.20 |
| Day Low | $32.99 |
| Volume | 1,821,445 |
Stock Information
| Shares Outstanding | 111.42M |
| Total Debt | $5.25M |
| Cash Equivalents | $250.76M |
| Net Income | $-152.09M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $3.77B |
| EPS (TTM) | $-1.41 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $3.52B |
| Income | $-152.09M |
| Book/sh | $2.15 |
| Cash/sh | $2.25 |
| Employees | 136 |
Financial Ratios
| Quick Ratio | 11.88 |
| Current Ratio | 12.12 |
| Debt/Eq | 2.20 |
Returns & Margins
| ROA | -44.13% |
| ROE | -74.73% |
Ownership
| Insider Ownership | 7.14% |
| Institutional Ownership | 93.97% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -29.28 |
| P/B | 15.74 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $42.36 |
Technical Indicators
| SMA20 | $29.77 |
| SMA50 | $22.82 |
| SMA200 | $16.44 |
| RSI | 69.14 |
| ATR | 2.9361 |
| Shares Float | 97.21M |
| Short Float | 15.58% |
| Short Ratio | 7.01 |
| Volatility | -0.20 |
| Rel Volume | 0.46 |
Performance History
| Week | -11.38% |
| Month | +66.47% |
| Quarter | +140.30% |
| 6 Months | +120.98% |
| YTD | +196.06% |
| Year | +258.92% |
| 3 Years | +55.59% |
| 10 Years | +87.11% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $33.81 | 1,821,500 |
| 2026-08-31 | $33.75 | 2,728,900 |
| 2026-08-27 | $37.18 | 1,988,700 |
| 2026-08-26 | $37.08 | 2,815,300 |
| 2026-08-25 | $37.46 | 2,146,600 |
| 2026-08-24 | $38.15 | 3,714,300 |
| 2026-08-21 | $38.66 | 4,641,200 |
| 2026-08-20 | $39.66 | 8,540,900 |
| 2026-08-19 | $38.60 | 8,262,300 |
| 2026-08-18 | $35.11 | 23,980,300 |
| 2026-08-17 | $21.43 | 1,267,100 |
| 2026-08-14 | $21.63 | 1,588,600 |
| 2026-08-13 | $22.48 | 839,400 |
| 2026-08-12 | $23.35 | 1,454,100 |
| 2026-08-11 | $23.63 | 833,900 |
| 2026-08-10 | $22.67 | 1,331,100 |
| 2026-08-07 | $22.82 | 2,678,300 |
| 2026-08-06 | $24.19 | 3,537,800 |
| 2026-08-05 | $21.85 | 1,772,200 |
| 2026-08-04 | $21.87 | 3,426,200 |
| 2026-08-03 | $20.17 | 1,685,200 |
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Motley Fool âĸ 2026-09-01T13:50:00Z
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Motley Fool âĸ 2026-08-30T16:35:00Z
Oracle Stock And 2 High Growth Picks Backed By Rising Credit Demand
Simply Wall St. âĸ 2026-08-27T16:24:44Z
Oracle Stock And 2 Growth Picks With Strong Earnings Potential
Simply Wall St. âĸ 2026-08-26T04:38:01Z
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Motley Fool âĸ 2026-08-21T22:00:54Z
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
Insider Monkey âĸ 2026-08-21T21:58:08Z
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
Stocktwits âĸ 2026-08-21T03:57:42Z
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
Zacks âĸ 2026-08-19T16:18:00Z
Amylyx Pharmaceuticals (AMLX) Posts Phase 3 Avexitide Win And Follows With Equity Raise
Simply Wall St. âĸ 2026-08-19T09:11:42Z
Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today?
Stocktwits âĸ 2026-08-19T01:54:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $0 | $124,633,000 | $25,441,000 | $2,993,000 |
| Cost Of Revenue | $0 | $124,633,000 | $25,441,000 | $2,993,000 |
| Total Revenue | $0 | $87,371,000 | $380,786,000 | $22,230,000 |
| Operating Revenue | $0 | $87,371,000 | $431,433,000 | $27,104,000 |
| Expenses | ||||
| Total Expenses | $153,291,000 | $343,048,000 | $341,984,000 | $223,571,000 |
| Other Income Expense | $-700,000 | $-60,268,000 | $-660,000 | $-551,000 |
| Other Non Operating Income Expenses | $-700,000 | $-1,214,000 | $-660,000 | $-551,000 |
| Net Non Operating Interest Income Expense | $9,302,000 | $13,809,000 | $16,155,000 | $4,291,000 |
| Operating Expense | $153,291,000 | $218,415,000 | $316,543,000 | $220,578,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Other Operating Expenses | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Net Interest Income | $9,302,000 | $13,809,000 | $16,155,000 | $4,291,000 |
| Interest Income | $9,302,000 | $13,809,000 | $16,155,000 | $4,291,000 |
| Normalized Income | $-144,735,000 | $-242,748,054 | $49,271,000 | $-198,375,000 |
| Net Income From Continuing And Discontinued Operation | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Total Operating Income As Reported | $-153,291,000 | $-314,731,000 | $38,802,000 | $-201,341,000 |
| Net Income Common Stockholders | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Net Income | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Net Income Including Noncontrolling Interests | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Net Income Continuous Operations | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Pretax Income | $-144,689,000 | $-302,136,000 | $54,297,000 | $-197,601,000 |
| Special Income Charges | $0 | $-59,054,000 | $0 | - |
| Interest Income Non Operating | $9,302,000 | $13,809,000 | $16,155,000 | $4,291,000 |
| Operating Income | $-153,291,000 | $-255,677,000 | $38,802,000 | $-201,341,000 |
| Gross Profit | $0 | $-37,262,000 | $355,345,000 | $19,237,000 |
| Per Share | ||||
| Diluted EPS | $-1.53 | $-4.43 | $0.70 | $-3.39 |
| Basic EPS | $-1.53 | $-4.43 | $0.73 | $-3.39 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-59,054 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-152,766,000 | $-195,719,000 | $39,890,000 | $-200,854,000 |
| Total Unusual Items | $0 | $-59,054,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $0 | $-59,054,000 | $0 | - |
| Reconciled Depreciation | $525,000 | $904,000 | $1,088,000 | $487,000 |
| EBITDA (Bullshit earnings) | $-152,766,000 | $-254,773,000 | $39,890,000 | $-200,854,000 |
| EBIT | $-153,291,000 | $-255,677,000 | $38,802,000 | $-201,341,000 |
| Diluted Average Shares | $94,565,567 | $68,142,158 | $69,991,340 | $58,495,587 |
| Basic Average Shares | $94,565,567 | $68,142,158 | $67,234,465 | $58,495,587 |
| Diluted NI Availto Com Stockholders | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Tax Provision | $46,000 | $-393,000 | $5,026,000 | $774,000 |
| Restructuring And Mergern Acquisition | $0 | $22,851,000 | $0 | - |
| Research And Development | $90,404,000 | $104,084,000 | $128,187,000 | $93,450,000 |
| Selling General And Administration | $62,887,000 | $114,331,000 | $188,356,000 | $127,128,000 |
| Other Special Charges | - | $36,203,000 | - | - |
| Other Gand A | - | - | - | - |
Fetched: 2026-08-29
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Total Assets | $332,645,000 | $193,634,000 | $517,454,000 | $391,453,000 |
| Total Non Current Assets | $8,974,000 | $4,202,000 | $52,788,000 | $9,320,000 |
| Other Non Current Assets | $3,483,000 | $1,470,000 | $46,377,000 | $1,185,000 |
| Current Assets | $323,671,000 | $189,432,000 | $464,666,000 | $382,133,000 |
| Other Current Assets | $6,604,000 | $12,484,000 | $14,931,000 | $10,113,000 |
| Receivables | $88,000 | $447,000 | $40,050,000 | $15,306,000 |
| Accounts Receivable | $88,000 | $447,000 | $40,050,000 | $15,306,000 |
| Cash Cash Equivalents And Short Term Investments | $316,979,000 | $176,501,000 | $371,362,000 | $346,945,000 |
| Cash And Cash Equivalents | $226,651,000 | $77,391,000 | $170,201,000 | $62,526,000 |
| Inventory | - | $0 | $38,323,000 | $9,769,000 |
| Current Deferred Assets | - | - | - | $0 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $5,957,000 | $1,981,000 | $4,237,000 | $6,277,000 |
| Long Term Debt And Capital Lease Obligation | $4,698,000 | $463,000 | $1,980,000 | $4,237,000 |
| Current Debt And Capital Lease Obligation | $1,259,000 | $1,518,000 | $2,257,000 | $2,040,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $27,386,000 | $28,869,000 | $84,022,000 | $50,846,000 |
| Total Non Current Liabilities Net Minority Interest | $4,698,000 | $463,000 | $1,980,000 | $4,237,000 |
| Current Liabilities | $22,688,000 | $28,406,000 | $82,042,000 | $46,609,000 |
| Payables And Accrued Expenses | $11,374,000 | $16,896,000 | $62,995,000 | $29,338,000 |
| Payables | $3,519,000 | $2,939,000 | $22,061,000 | $6,257,000 |
| Accounts Payable | $3,519,000 | $2,939,000 | $22,061,000 | $6,257,000 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Other Current Liabilities | - | - | - | $4,596,000 |
| Other Payable | - | - | - | $1,358,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Total Equity Gross Minority Interest | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Stockholders Equity | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Gains Losses Not Affecting Retained Earnings | $404,000 | $-92,000 | $197,000 | $-86,000 |
| Other Equity Adjustments | $404,000 | $-92,000 | $197,000 | $-86,000 |
| Retained Earnings | $-751,427,000 | $-606,692,000 | $-304,949,000 | $-354,220,000 |
| Preferred Securities Outside Stock Equity | - | - | - | $0 |
| Other | ||||
| Ordinary Shares Number | $109,884,502 | $68,629,738 | $67,707,432 | $66,512,011 |
| Share Issued | $109,884,502 | $68,629,738 | $67,707,432 | $66,512,011 |
| Tangible Book Value | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Invested Capital | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Working Capital | $300,983,000 | $161,026,000 | $382,624,000 | $335,524,000 |
| Capital Lease Obligations | $5,957,000 | $1,981,000 | $4,237,000 | $6,277,000 |
| Total Capitalization | $305,259,000 | $164,765,000 | $433,432,000 | $340,607,000 |
| Additional Paid In Capital | $1,056,271,000 | $771,542,000 | $738,177,000 | $694,906,000 |
| Capital Stock | $11,000 | $7,000 | $7,000 | $7,000 |
| Common Stock | $11,000 | $7,000 | $7,000 | $7,000 |
| Long Term Capital Lease Obligation | $4,698,000 | $463,000 | $1,980,000 | $4,237,000 |
| Current Capital Lease Obligation | $1,259,000 | $1,518,000 | $2,257,000 | $2,040,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $10,055,000 | $9,992,000 | $16,790,000 | $15,231,000 |
| Current Accrued Expenses | $7,855,000 | $13,957,000 | $40,934,000 | $23,081,000 |
| Net PPE | $5,491,000 | $2,732,000 | $6,411,000 | $8,135,000 |
| Accumulated Depreciation | $-1,554,000 | $-1,359,000 | $-1,628,000 | $-540,000 |
| Gross PPE | $7,045,000 | $4,091,000 | $8,039,000 | $8,675,000 |
| Leases | $154,000 | $176,000 | $176,000 | $176,000 |
| Construction In Progress | $19,000 | $221,000 | $589,000 | $803,000 |
| Other Properties | $5,181,000 | $1,771,000 | $3,725,000 | $5,524,000 |
| Machinery Furniture Equipment | $1,691,000 | $1,923,000 | $3,549,000 | $2,172,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $90,328,000 | $99,110,000 | $201,161,000 | $284,419,000 |
| Finished Goods | - | $0 | - | $937,000 |
| Work In Process | - | $0 | - | $1,681,000 |
| Raw Materials | - | $0 | - | $7,151,000 |
| Preferred Stock | - | - | $0 | $0 |
Fetched: 2026-08-29
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-123,481,000 | $-167,804,000 | $10,678,000 | $-182,397,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-123,343,000 | $-167,647,000 | $11,919,000 | $-179,871,000 |
| Cash Flow From Continuing Operating Activities | $-123,343,000 | $-167,647,000 | $11,919,000 | $-179,871,000 |
| Investing Activities | ||||
| Capital Expenditure | $-138,000 | $-157,000 | $-1,241,000 | $-2,526,000 |
| Investing Cash Flow | $14,039,000 | $75,654,000 | $92,053,000 | $-238,988,000 |
| Cash Flow From Continuing Investing Activities | $14,039,000 | $75,654,000 | $92,053,000 | $-238,988,000 |
| Net Other Investing Changes | - | $-36,203,000 | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $257,029,000 | $348,000 | $3,543,000 | $431,789,000 |
| Cash Flow From Continuing Financing Activities | $257,029,000 | $348,000 | $3,543,000 | $431,789,000 |
| Net Other Financing Charges | $252,952,000 | $-1,784,000 | $-3,451,000 | $-2,847,000 |
| Issuance Of Capital Stock | - | - | $0 | $432,447,000 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
| Net Common Stock Issuance | - | - | $0 | $432,447,000 |
| Common Stock Issuance | - | - | $0 | $432,447,000 |
| Other | ||||
| End Cash Position | $227,636,000 | $78,837,000 | $170,920,000 | $63,245,000 |
| Beginning Cash Position | $78,837,000 | $170,920,000 | $63,245,000 | $50,380,000 |
| Effect Of Exchange Rate Changes | $1,074,000 | $-438,000 | $160,000 | $-65,000 |
| Changes In Cash | $147,725,000 | $-91,645,000 | $107,515,000 | $12,930,000 |
| Proceeds From Stock Option Exercised | $4,077,000 | $2,132,000 | $6,994,000 | $2,189,000 |
| Net Investment Purchase And Sale | $14,177,000 | $112,014,000 | $93,294,000 | $-236,462,000 |
| Sale Of Investment | $246,000,000 | $344,000,000 | $394,120,000 | $179,411,000 |
| Purchase Of Investment | $-231,823,000 | $-231,986,000 | $-300,826,000 | $-415,873,000 |
| Net PPE Purchase And Sale | $-138,000 | $-157,000 | $-1,241,000 | $-2,526,000 |
| Purchase Of PPE | $-138,000 | $-157,000 | $-1,241,000 | $-2,526,000 |
| Change In Working Capital | $-1,083,000 | $-45,831,000 | $-65,661,000 | $-1,641,000 |
| Change In Other Current Liabilities | $-1,162,000 | $-2,256,000 | $-2,041,000 | $-917,000 |
| Change In Other Current Assets | $1,730,000 | $1,954,000 | $1,568,000 | $1,179,000 |
| Change In Payables And Accrued Expense | $-6,018,000 | $-78,912,000 | $37,479,000 | $27,906,000 |
| Change In Accrued Expense | $-6,598,000 | $-59,810,000 | $21,597,000 | $26,052,000 |
| Change In Payable | $580,000 | $-19,102,000 | $15,882,000 | $1,854,000 |
| Change In Account Payable | $580,000 | $-19,102,000 | $15,882,000 | $1,854,000 |
| Change In Prepaid Assets | $3,984,000 | $2,675,000 | $-3,226,000 | $-5,221,000 |
| Change In Inventory | $0 | $-9,253,000 | $-73,129,000 | $-9,769,000 |
| Change In Receivables | $383,000 | $39,961,000 | $-24,744,000 | $-14,819,000 |
| Changes In Account Receivables | $359,000 | $39,602,000 | $-24,744,000 | $-15,306,000 |
| Other Non Cash Items | $-169,000 | $37,161,000 | - | - |
| Stock Based Compensation | $27,645,000 | $33,038,000 | $37,161,000 | $21,714,000 |
| Asset Impairment Charge | $0 | $118,680,000 | $0 | - |
| Amortization Of Securities | $-5,526,000 | $-9,856,000 | $-9,940,000 | $-2,056,000 |
| Depreciation Amortization Depletion | $525,000 | $904,000 | $1,088,000 | $487,000 |
| Depreciation And Amortization | $525,000 | $904,000 | $1,088,000 | $487,000 |
| Depreciation | $525,000 | $904,000 | $1,088,000 | $487,000 |
| Net Income From Continuing Operations | $-144,735,000 | $-301,743,000 | $49,271,000 | $-198,375,000 |
| Income Tax Paid Supplemental Data | - | $708,000 | $6,389,000 | $27,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Issuance Of Debt | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Change In Interest Payable | - | - | $0 | $0 |
Fetched: 2026-08-29